Evidence map›Paper›PMID 25859997›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2015

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.

R S Garfein, D G Catanzaro, T C Rodwell, E Avalos, R L Jackson, J Kaping, H Evasco, C Rodrigues, V Crudu, S-Y G Lin and 11 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Novel and reported compensatory mutations inFrontiers in microbiology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

  • Erratum issued
    Groessel, E [corrected to Groessl, E]
5 · Who and what money

Authors and funding

21 authors.

R S GarfeinDepartment of Medicine, University of California, San Diego, California, USA.
D G CatanzaroUniversity of Arkansas, Department of Biological Sciences, Fayetteville, Arkansas, USA.
T C RodwellDepartment of Medicine, University of California, San Diego, California, USA.
E AvalosDepartment of Family Medicine and Public Health, University of California, San Diego, California, USA.
R L JacksonDepartment of Medicine, University of California, San Diego, California, USA.
J KapingDepartment of Medicine, University of California, San Diego, California, USA.
H EvascoTropical Disease Foundation, Inc, Philippine Institute of Tuberculosis Building, Makati City, Philippines.
C RodriguesHinduja National Hospital, Mumbai, India.
V CruduMicrobiology and Morphology Laboratory, Institute of Phthisiopneumology, Chisinau, Moldova.
S-Y G LinCalifornia Department of Public Health, Richmond, California, USA.
E Groessl
E GroesselDepartment of Family Medicine and Public Health, University of California, San Diego, California, USA.
N HilleryDepartment of Family Medicine and Public Health, University of California, San Diego, California, USA.
A TrollipDepartment of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa.
T GaniatsDepartment of Family Medicine and Public Health, University of California, San Diego, California, USA.
T C VictorDepartment of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa.
K EisenachDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
F ValafarUniversity of Arkansas, Department of Biological Sciences, Fayetteville, Arkansas, USA.
J ChannickDepartment of Medicine, University of California, San Diego, California, USA.
L QianDepartment of Microbiology, University of Hawaii, Honolulu, Hawaii, USA.
A CatanzaroDepartment of Medicine, University of California, San Diego, California, USA.

Funding

Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant TuberculosisU01AI082229 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CATANZARO, ANTONINO · 2009 to 2013
$10.9M
Evolutionary and Functional Significance of Novel Mutations in MDR-XDR TBR01AI105185 · NIAID · SAN DIEGO STATE UNIVERSITY · PI VALAFAR, FARAMARZ · 2013 to 2021
$5.3M
Binational Transmission of Multidrug-Resistant Tuberculosis, California & MexicoK01AI083784 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2009 to 2012
$487k
NIAID NIH HHS K01 AI083784NIAID NIH HHS K01-AI083784NIAID NIH HHS R01 AI105185NIAID NIH HHS U01 AI082229NIAID NIH HHS U01-AI082229
6 · The paper itself

Abstract

objectiveTo develop and evaluate rapid, molecular-based drug susceptibility testing (DST) for extensively drug-resistant tuberculosis (XDR-TB), we assembled a phenotypically and genotypically diverse collection of Mycobacterium tuberculosis isolates from patients evaluated for drug resistance in four high-burden countries.

methodsM. tuberculosis isolates from India (n = 111), Moldova (n = 90), the Philippines (n = 96), and South Africa (n = 103) were selected from existing regional and national repositories to maximize phenotypic diversity for resistance to isoniazid, rifampin (RMP), moxifloxacin, ofloxacin, amikacin, kanamycin, and capreomycin. MGIT™ 960 was performed on viable isolates in one laboratory using standardized procedures and drug concentrations. Genetic diversity within drug resistance phenotypes was assessed.

resultsNineteen distinct phenotypes were observed among 400 isolates with complete DST results. Diversity was greatest in the Philippines (14 phenotypes), and least in South Africa (9 phenotypes). Nearly all phenotypes included multiple genotypes. All sites provided isolates resistant to injectables but susceptible to fluoroquinolones. Many patients were taking drugs to which their disease was resistant. DISCUSSION: Diverse phenotypes for XDR-TB-defining drugs, including resistance to fluoroquinolones and/or injectable drugs in RMP-susceptible isolates, indicate that RMP susceptibility does not ensure effectiveness of a standard four-drug regimen. Rapid, low-cost DST assays for first- and second-line drugs are thus needed.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsChildChild, PreschoolExtensively Drug-Resistant TuberculosisFemaleGenotypeHumansIndiaMaleMicrobial Sensitivity TestsMiddle AgedMoldovaAntitubercular Agents

Identifiers

PMID25859997
PMCPMC4494864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.